BamSEC and AlphaSense Join Forces
Learn More

Seelos Therapeutics Inc.

OTC: SEELQ    
Share price (12/20/24): $0.27    
Market cap (12/20/24): $116 thousand
Search in Documents
Key Exhibits
External Links

Material Contracts Filter

EX-10.1
from 8-K 5 pages Agreement
12/34/56
EX-10.1
from 8-K 11 pages Holder of Warrants Issued in December 2023 and January 2024 Re: Inducement Offer to Exercise Warrants Issued in December 2023 and January 2024 Dear Holder
12/34/56
EX-10.2
from 8-K 20 pages Placement Agency Agreement
12/34/56
EX-10.1
from 8-K 43 pages Securities Purchase Agreement
12/34/56
EX-10.2
from 8-K 10 pages January 26, 2024 Seelos Therapeutics, Inc. 300 Park Avenue, 2nd Floor New York, New York 10022 Attention: Raj Mehra President, Chief Executive Officer and Chairman of the Board of Directors Re: Placement Agency Agreement Dear Mr. Mehra
12/34/56
EX-10.1
from 8-K 43 pages Securities Purchase Agreement
12/34/56
EX-10.2
from 8-K 3 pages 1. Note. Reference Is Hereby Made to That Certain Convertible Promissory Note No. 1, Issued by Seelos Therapeutics, Inc., a Nevada Corporation (The “Company”), on November 23, 2021, as Amended on December 10, 2021, February 8, 2023 and May 19, 2023 (As So Amended, the “Note”), in the Initial Principal Amount of $22,000,000 and Due November 23, 2024, to Lind Global Asset Management V, LLC, a Delaware Limited Liability Company (The “Holder”). Capitalized Terms Used but Not Otherwise Defined in This Letter Agreement (This “Agreement”) Shall Have the Meaning Ascribed to Them in the Note
12/34/56
EX-10.1
from 8-K 37 pages Securities Purchase Agreement
12/34/56
EX-10.1
from 8-K 8 pages Amendment No. 1 to Securities Purchase Agreement
12/34/56
EX-10.1
from 8-K 36 pages Securities Purchase Agreement
12/34/56
EX-10.8
from 10-K 3 pages Seelos Therapeutics, Inc. Non-Employee Director Compensation Policy
12/34/56
EX-10.1
from 8-K 4 pages Amendment No. 5 to Asset Purchase Agreement
12/34/56
EX-10.1
from 8-K 12 pages Seelos Therapeutics, Inc. Amended and Restated Employment Agreement
12/34/56
EX-10.2
from 8-K 17 pages Security Agreement
12/34/56
EX-10.2
from 8-K 15 pages Seelos Therapeutics, Inc. Common Stock Purchase Agreement
12/34/56
EX-10.1
from 8-K 41 pages Securities Purchase Agreement
12/34/56
EX-10.1
from 8-K 42 pages Exclusive License Agreement
12/34/56
EX-10.1
from 8-K 5 pages Acknowledgment and Termination Agreement
12/34/56
EX-10.2
from 10-Q 4 pages Seelos Therapeutics, Inc. Non-Employee Director Compensation Policy
12/34/56
EX-10.1
from 8-K 3 pages Amendment No. 4 to Asset Purchase Agreement
12/34/56